Market closedNon-fractionalADR
Takeda Pharmaceutical/TAK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Ticker
TAK
Sector
Healthcare
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Tokyo, Japan
Employees
49,281
Website
www.takeda.com
TAK Metrics
BasicAdvanced
$44B
Market cap
23.07
P/E ratio
$0.59
EPS
0.50
Beta
$1.22
Dividend rate
8.94%
Dividend yield
Price and volume
Market cap
$44B
Beta
0.5
Dividend rate
$1.22
Financial strength
Current ratio
1.106
Quick ratio
0.5
Long term debt to equity
70.997
Total debt to equity
76.046
Dividend payout ratio (TTM)
199.34%
Interest coverage (TTM)
4.27%
Management effectiveness
Return on assets (TTM)
1.57%
Return on equity (TTM)
2.12%
Valuation
Price to earnings (TTM)
23.07
Price to revenue (TTM)
0.772
Price to book
0.91
Price to tangible book (TTM)
-2.76
Price to free cash flow (TTM)
13.964
Dividend yield (TTM)
8.94%
Growth
Revenue change (TTM)
5.87%
Earnings per share change (TTM)
-54.86%
3-year revenue growth (CAGR)
10.06%
3-year earnings per share growth (CAGR)
-27.47%
3-year dividend per share growth (CAGR)
1.46%
What the Analysts think about TAK
Analyst Ratings
Majority rating from 4 analysts.
TAK Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
¥1.1T
-5.43%
Net income
-¥3B
-102.85%
Profit margin
-0.28%
-102.94%
TAK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Actual
¥29
-¥16
¥34
Expected
-
-
-
Surprise
-
-
-
TAK News
AllArticlesVideos
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Seeking Alpha·5 hours ago
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
Seeking Alpha·1 week ago
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Takeda Pharmaceutical stock?
Takeda Pharmaceutical (TAK) has a market cap of $44B as of July 27, 2024.
What is the P/E ratio for Takeda Pharmaceutical stock?
The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 23.07 as of July 27, 2024.
Does Takeda Pharmaceutical stock pay dividends?
Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of July 27, 2024, the dividend rate is $1.222 and the yield is 8.94%. Takeda Pharmaceutical has a payout ratio of 199.34% on a trailing twelve-month basis.
When is the next Takeda Pharmaceutical dividend payment date?
The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.
What is the beta indicator for Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Takeda Pharmaceutical stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.